IMRN - Immuron to get European patent for drug composition to treat bacterial infection

• Immuron ( NASDAQ: IMRN ) said the European Patent Office intends to grant the company a patent related to compositions and methods for treatment and/or preventing diseases due to the bacterium Clostridioides difficile.
• Clostridioides difficile infection is a disease of the large intestine caused by toxins produced by the spore forming bacterium Clostridioides difficile, according to the company's July 7 press release.
• The Austrialn company said a notification of the intent to grant European Patent 14784945.9, titled 'Methods and Compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease,' was received from the agency.

For further details see: